BASF's new bioactive ingredient the wellness elixir for healthy skin
The active ingredient is a 100% natural extract from the chaga mushroom, obtained using an innovative eco-friendly technology: subcritical water extraction.
Extracted from the chaga mushroom (Inonotus obliquus), native to the Northern Canadian forest, Inolixir is the most recent addition to BASF’s portfolio of bioactive ingredients. With its antioxidant and anti-inflammatory properties, it fortifies the skin’s natural protection system by strengthening barrier function and the microvascular network – working on all fronts to return skin to a healthier condition, with visible results on fine lines, dark-circles and redness.
A superfood ingredient for healthy skin
The chaga mushroom is a superfood renowned for various health benefits and has both traditional and modern uses. With Inolixir (INCI: Glycerin (and) Water (and) Inonotus Obliquus (Mushroom) Extract), BASF scientists have now harnessed the chaga mushroom’s power for use in skin care products, catering to the worldwide consumer trend of changing perceptions of beauty and the increasing popularity of a more holistic approach. This often involves consumers making lifestyle changes and, importantly, looking for cosmetic products with natural ingredients.
A powerful, dual action bioactive ingredient offering quick and long-lasting results
Inolixir works in two ways: first, it offers a wellness approach proven to be effective on tired and stressed skin. Study participants reported that Inolixir was as effective as a 5-day relaxation cure in mitigating fatigue lines, dark circles and dullness. Second, the bioactive ingredient presents dermocosmetic solutions for sensitive skin: it offers anti-redness and anti-dullness benefits, leading 85% of study participants to perceive a health benefit for their skin and 91% to report increased skin comfort within 7 to 28 days of application.
Inolixir is a hyper-concentrated bioactive ingredient, benefitting from all the nutrients and properties of the chaga mushroom thanks to an innovative and eco-friendly technology: subcritical water extraction (SWE). Instead of organic solvents, this method uses pressurized water heated to between 100 °C and 374 °C for extraction. In vitro tests have proven that SWE extracts phytochemicals more efficiently than other common methods, such as conventional hydroethanolic extraction and water extraction.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance